ClinicalTrials.gg
RecruitingNCT07940179PSMA-PETUpdated Nov 16, 2026

Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography

An interventional study of PET PSMA tracer in Prostate Cancer and Other Cancers, sponsored by Jean-Mathieu Beauregard. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Jean-Mathieu Beauregard · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Nov 2021, registered Nov 2026).
  • Started Nov 2021; still recruiting 5 years later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 712 studies in Prostatic Neoplasms with a site in Canada — 120 open to participants now, 222 under way, 64 of them phase 3. Prostatic Neoplasms · Canada.

Planned enrollment
3rd of 635
5,000 · median 100
Started
2021
with 33 others
No phase
189 of 712
46 open now
Primary completion
2031-12
later than 209 of 221 live
Registered
712th of 712
by date

Among the 712 studies in Prostatic Neoplasms with a site in Canada, this one is the 3rd largest by planned enrollment of the 635 interventional ones that give a count, is one of 34 that started in 2021, is one of 189 with no phase, reaches primary completion later than 209 of the 221 other live ones, and was the 712th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

120 of the 712 studies in Prostatic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Prostatic Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to make non-approved PSMA radioligands available at CHU de Québec - Université Laval, while assessing their safety. Our hypothesis is that all the PSMA PET radioligand are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of PSMA-PET will be explored in our clinical setting.

03

Conditions studied

  • Prostate Cancer
  • Other Cancers

Browse trials for

Keywords

  • prostate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Reception of a procedure request for PSMA-PET

Exclusion criteria

Exclusion Criteria:

  1. Incapacity to provide
  2. Pregnancy, unless there has been a discussion between the participant and a nuclear medicine physician investigator about the potential clinical benefits vs. the potential risks for the fetus, in the context of the participant's medical condition, and that this discussion is documented in the nuclear medicine physician's clinical report.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    PSMA-PET

    Drug: PET PSMA tracer

Interventions

  • DrugPET PSMA tracer

    Administration of a PSMA tracer for PET

06

What researchers measure

Primary outcomes

  1. Proportion of Participants with PSMA PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .

    Time frame: up to 1 week

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2031, 121 months after the start.

Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 121 months is above that.

Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Nov 4, 2021
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2032
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940179
Lead sponsor
Jean-Mathieu Beauregard
Responsible party
Jean-Mathieu Beauregard (Nuclear medicine physician, CHU de Quebec-Universite Laval) — Sponsor-investigator
First posted
Nov 16, 2026
Start date
Nov 4, 2021
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Marie-Christine Dubé, Ph.D.
Contact
marie-christine.dube@crchudequebec.ulaval.ca
418-525-4444 ext. 67708
Jean-Mathieu Beauregard, MD
principal investigator · CHU de Quebec (Université Laval)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion